Rise of Chronic Diseases Leads to Growing Investment in Stem Cell Research

NEW YORK, July 11, 2018 /PRNewswire/ --

According to a report published by Transparency Market Research, the global stem cell market is expected to reach US 270.5 Billion by 2025, while increasing at a compound annual growth rate of 13.8% during the period from 2017 to 2025. From a product perspective, the global stem cell market can be divided into adult stem cells and embryonic stem cells. Adult stem cells hold the largest market share due to their low risk of rejection. From a geography perspective, North America accounts for a leading share in the market due to rising instances of chronic diseases, increasing research investment and technological progress. The stem cells market in North America is projected to be worth USD 167.33 Billion by 2025. International Stem Cell Corp. (OTC: ISCO), Sangamo Therapeutics Inc. (NASDAQ: SGMO), Cellular Biomedicine Group Inc. (NASDAQ: CBMG), Vericel Corporation (NASDAQ: VCEL), Athersys Inc. (NASDAQ: ATHX)

The lead analyst of the report explains, "The growing prevalence of chronic diseases and increasing investments of pharmaceutical and biopharmaceutical companies in stem cell research are the key driving factors for the stem cells therapeutics market. The growing number of stem cell donors, improved stem cell banking facilities, and increasing research and development are other crucial factors serving to propel the market."

International Stem Cell Corp. (OTCQB: ISCO) announced yesterday that, "its wholly owned subsidiary, Lifeline Cell Technology (LCT), has expanded its business and manufacturing capabilities to fulfill current and forecasted demand.

LCT has demonstrated stable manufacturing and revenue growth over the last five years. In 2017 alone, the annual revenue growth outperformed 2016 by over 20%. And in Q1 2018, LCT experienced more than a 50% increase in sales growth from the prior year quarter. During this time, several projects have been completed that greatly improved LCT's manufacturing capabilities, allowing LCT to meet the growing demand of its products.

The upgrades have been made in all operational departments, including new equipment that has significantly improved its manufacturing and testing capabilities, now handling quadruple its original batch sizes. LCT has also hired additional staff in manufacturing and is in the process of expanding its facilities to include a formulation lab, a warehouse, and more working space.

'We continue to receive positive feedback from both new and current customers on the performance of our products and the efficiency of our distribution channels. Customer loyalty, our growing catalog of items, and increasing research and development spent in the biomedical market should help us continue our sales growth' commented Andrey Semechkin, PhD, Co-Chairman and Chief Executive Officer of ISCO.

Lifeline® Cell Technology develops manufactures and distributes high quality cells, media, and reagents for the research market world-wide. LCT's modern laboratories and strict Quality Assurance provide high levels of consistent value to the research community. LCT conducts human cell in vitro research, product development, and manufacturing at the facilities in Oceanside, CA and Frederick, MD. The laboratories include all the necessary equipment used to manufacture, package, test, store, and distribute primary human cells and cell culture media. We are continuing to expand the cell culture facilities to include therapeutic cell research, development, and production in the cGMP suites."

Sangamo Therapeutics Inc. (NASDAQ: SGMO) is focused on translating ground-breaking science into genomic therapies that transform patients' lives using the Company's platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo recently announced that the California Institute for Regenerative Medicine (CIRM) has awarded an USD 8 Million grant for Sangamo to evaluate ST-400, a gene-edited cell therapy candidate for people with transfusion-dependent beta-thalassemia. The Company's Investigational New Drug Application for ST-400 has been accepted by the U.S. Food and Drug Administration, and the first site is now initiated for a Phase 1/2 clinical trial. "CIRM plays a critical role in funding the rigorous evaluation of new stem cell therapies, and we are very pleased to receive CIRM's support for the study of ST-400 for the treatment of transfusion-dependent beta-thalassemia," said Edward Conner, M.D., Chief Medical Officer at Sangamo.

Cellular Biomedicine Group Inc. (NASDAQ: CBMG), a clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies for degenerative diseases, recently announced 48-week clinical data from the Phase I clinical trial in China for its allogeneic adipose-derived mesenchymal progenitor cell off-the-shelf therapy AlloJoinTM for Knee Osteoarthritis (KOA). The 48-week analysis of study data of 22 patients demonstrated AlloJoinTM off-the-shelf allogeneic stem cell therapy for KOA to have good safety tolerance and early signs of efficacy in preventing cartilage deterioration. "We are very encouraged by the latest data from our AlloJoinTM Phase I trial in China which demonstrates good safety and early efficacy for the prevention of cartilage deterioration. The recent regulatory guidelines issued by the CFDA have set a clearer clinical and commercialization pathway for our AlloJoinTM platform," said Tony Liu, CEO of the Company.

Vericel Corporation (NASDAQ: VCEL) is a leader in advanced cell therapies for the sports medicine and severe burn care markets.  The company markets two cell therapy products in the United States. The Company recently announced the publication of results from the MACI® (autologous cultured chondrocytes on porcine collagen membrane) Phase 3 SUMMIT  Extension Study in the American Journal of Sports Medicine. The results demonstrated that the significantly greater improvements in Knee injury and Osteoarthritis Outcome Score pain and function scores for MACI versus microfracture shown in the two-year Phase 3 SUMMIT (Superiority of MACI Implant Versus Microfracture Treatment) study were maintained over the additional three-year follow-up in the SUMMIT Extension Study. Nick Colangelo, Vericel's President and Chief Executive Officer, said, "It is important to both clinicians and patients that MACI, in addition to demonstrating significant improvements compared to microfracture as early as one year, maintains improvements over microfracture out to at least five years."

Athersys Inc. (NASDAQ: ATHX) is an international biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem cell therapy product, a patented, adult-derived "off-the-shelf" stem cell product, initially for disease indications in the neurological, cardiovascular, and inflammatory and immune disease areas, and has several ongoing clinical trials evaluating this potential regenerative medicine product. The Company and The University of Texas Health Science Center at Houston, recently announced plans to conduct a Phase 2 clinical trial evaluating Athersys' MultiStem® cell therapy for early treatment and prevention of complications after severe traumatic injury. Athersys will provide the investigational clinical product for the conduct of the trial, as well as regulatory and operational support, as its contribution to the trial. Dr. Charles S. Cox Jr., the George and Cynthia Mitchell Distinguished Chair in Neurosciences in the Department of Pediatric Surgery and co-Director of the Red Duke Trauma Institute at Memorial Hermann-Texas Medical Center, will serve as principal investigator. "Our prior research demonstrates that administration of MultiStem following acute neurological injury can help improve recovery and reduce the occurrence or severity of certain complications, so we are excited about the clinical potential in this area," said Dr. Charles S. Cox Jr.

Subscribe Now! Watch us report LIVE https://www.youtube.com/FinancialBuzzMedia

Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz

Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz

Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/

About FinancialBuzz.com 

FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the 'Site') is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For International Stem Cell Corp., financial news dissemination and PR services, FinancialBuzz.com has been compensated four thousand dollars by meridian ventures. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: http://www.financialbuzz.com.

For further information:
Media Contact:
[email protected]
+1-877-601-1879

Url: http://www.FinancialBuzz.com

SOURCE FinancialBuzz.com